Department of Pathology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama, Japan.
Division of Pathophysiology, Okayama University Graduate School of Health Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.
Med Mol Morphol. 2020 Sep;53(3):149-155. doi: 10.1007/s00795-019-00241-6. Epub 2020 Jan 2.
Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach is mainly associated with Helicobacter pylori infection, and H. pylori eradication therapy is often effective. However, 20-30% of the cases of MALT lymphoma are resistant to the eradication therapy, and translocation of the API2-MALT1 gene is often found in these cases. Most cases without translocation of API2-MALT1 are localized to the stomach, whereas some cases with this translocation are a more advanced stage of MALT lymphoma that spreads to other organs. The c-Met receptor is a prognostic factor involved in infiltration and metastasis in many malignant tumors, including gastric, pancreatic, lung, and kidney cancer. In the present study, the expression of c-Met in 43 cases of gastric MALT lymphomas was immunohistochemically examined and compared with clinicopathological factors. To elucidate the significance of c-Met in MALT lymphoma, the expression intensity of c-Met in 22 API2-MALT1 translocation-positive and 21 API2-MALT1 translocation-negative cases was scored, compared, and examined. The immunohistochemistry analysis revealed strong staining for c-Met in 21 API2-MALT1 translocation-positive cases and in 1 translocation-negative case (P = 0.00). This result indicates the relationship between strong expression of c-Met and the progression of MALT lymphoma with API2-MALT1 gene translocation.
胃黏膜相关淋巴组织(MALT)结外边缘区淋巴瘤主要与幽门螺杆菌(H. pylori)感染相关,H. pylori 根除治疗通常有效。然而,20-30%的 MALT 淋巴瘤病例对根除治疗有耐药性,这些病例中经常发现 API2-MALT1 基因易位。大多数没有 API2-MALT1 易位的病例局限于胃,而一些有这种易位的病例则处于更晚期的 MALT 淋巴瘤阶段,会扩散到其他器官。c-Met 受体是包括胃癌、胰腺癌、肺癌和肾癌在内的许多恶性肿瘤中涉及浸润和转移的预后因素。在本研究中,通过免疫组织化学检查了 43 例胃 MALT 淋巴瘤中 c-Met 的表达,并与临床病理因素进行了比较。为了阐明 c-Met 在 MALT 淋巴瘤中的意义,对 22 例 API2-MALT1 易位阳性和 21 例 API2-MALT1 易位阴性病例的 c-Met 表达强度进行了评分、比较和检查。免疫组织化学分析显示,21 例 API2-MALT1 易位阳性病例和 1 例易位阴性病例中 c-Met 染色强(P = 0.00)。这一结果表明 c-Met 的强表达与具有 API2-MALT1 基因易位的 MALT 淋巴瘤的进展有关。